# Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)

> **NCT07218172** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 197 (actual)

## Conditions studied

- Severe Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07218172
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-24
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-04-24
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218172, "Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT07218172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*